Takeda takes rights to obesity drugs (Dealscape

Takeda Pharmaceutical Co. Ltd., Japan's biggest drugmaker, agreed Monday to pay $75 million upfront to Amylin Pharmaceuticals Inc. to develop and market a variety of its compounds to fight obesity in a deal that could eventually pay $1 billion.

Amylin, a San Diego firm with diabetes drugs Symlin and Byetta on the market, said it has two compounds in Phase 2 development aimed at helping consumers lose weight. The drugs, a combination called Pramlintide/Metreleptin and another called Davalintide, have been in development since 2006, but the firm said it is too soon to estimate when it might seek approval from the U.S. Food and Drug Administration to market them.

This is a free content preview. Subscribers enjoy access to all stories in full as well as second-to-none market intelligence.

Dig deeper, with Pipeline.

873 in-depth reports of M&A deals in the Healthcare sector
613 company pages related to Pharmaceuticals
121 articles related to Takeda Pharmaceutical Co. Ltd.
35 articles related to Amylin Pharmaceuticals Inc.
10 years of news and analysis archives from the voice of The Deal Economy

Most searched keywords

Skadden Arps
Amusement parks
Deb Shops
Windstream Corp.
Diedrich Coffee
Hanna Andersson
Tween Brands
Entertainment
Lazard
Lyondell Chemical

Forward-looking intelligence allows you time to act. View this video on our restructuring content to see how you can benefit from our expertise.
NOT A SUBSCRIBER? Takeda takes rights to obesity drugs Posted on November 3, 2009 5:30 AM Takeda Pharmaceutical Co. Ltd., Japan's biggest drugmaker, agreed Monday to pay $75 million upfront to Amylin Pharmaceuticals Inc. to develop and market a variety of its compounds to fight obesity in a deal that could eventually pay $1 billion. Amylin, a San Diego firm with diabetes drugs Symlin and Byetta on the market, said it has two compounds in Phase 2 development aimed at helping consumers lose weight. The drugs, a combination called Pramlintide/Metreleptin and another called Davalintide, have been in development since 2006, but the firm said it is too soon to estimate when it might seek approval from the U.S. Food and Drug Administration to market them. This is a free content preview. Subscribers enjoy access to all stories in full as well as second-to-none market intelligence. Dig deeper, with Pipeline. 873 in-depth reports of M&A deals in the Healthcare sector 613 company pages related to Pharmaceuticals 121 articles related to Takeda Pharmaceutical Co. Ltd. 35 articles related to Amylin Pharmaceuticals Inc. 10 years of news and analysis archives from the voice of The Deal Economy Most searched keywords Skadden Arps Amusement parks Deb Shops Windstream Corp. Diedrich Coffee Hanna Andersson Tween Brands Entertainment Lazard Lyondell Chemical		EXISTING USERS Username Password Forget your password? Missing a product?

Sales Contact Michael Crosby mcrosby@thedeal.com 212.313.9325	Media Contact Martha Brown mbrown@thedeal.com 212.313.9218
Signing in signifies that you agree to our terms and conditions. View our privacy policy.